Bookmark
Forward
QuickView for Rosuvastatin (compound)
PubChem
| Name: | rosuvastatin |
|---|---|
| PubChem Compound ID: | 10814617 |
| Molecular formula: | C30H22Cl2N2 |
| Molecular weight: | 481.415 g/mol |
DrugBank
Identification
| Name: | rosuvastatin |
|---|---|
| Name (isomeric): | DB01098 |
| Drug Type: | small molecule |
| Synonyms: |
Rosuvastatin calcium; ZD-4522
|
| Brand: | Rosvel, Rovartal, Rosimol, Visacor, Cirantan, Crestor, Rosedex, Rosuvast, Vivacor, Astende, Rosustatin, Provisacor, Cresadex, Razel, Rosumed, Rosuvas, Sinlip, Simestat |
| Category: | HMG-CoA Reductase Inhibitors, Anticholesteremic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors |
| CAS number: | 287714-41-4 |
Pharmacology
| Indication: | Used as an adjunct to dietary therapy to treat primary hypercholesterolemia (heterozygous familial and nonfamilial), mixed dyslipidemia and hypertriglyceridemia. Also indicated for homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies or when other such therapies are not available. |
|---|---|
| Pharmacology: |
Rosuvastatin is a synthetic, enantiomerically pure antilipemic agent. It is used to lower total cholesterol, low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), non-high density lipoprotein-cholesterol (non-HDL-C), and trigleride (TG) plasma concentrations while increasing HDL-C concentrations. High LDL-C, low HDL-C and high TG co...
show more » |
| Mechanism of Action: |
Rosuvastatin is a competitive inhibitor of HMG-CoA reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis. Rosuvastatin acts primarily in the liver. Decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low density lipoprotein (LDL) recepto...
show more » |
| Absorption: | Bioavailability is approximately 20% |
| Protein binding: | 90% bound to plasma proteins (mostly albumin) |
| Biotransformation: | Not extensively metabolized. Only ~10% is excreted as metabolite. Cytochrome P450 (CYP) 2C9 is primarily responsible for the formation of rosuvastatin's major metabolite, N-desmethylrosuvastatin. N-desmethylrosuvastatin has approximately 50% of the pharmacological activity of its parent compound in vitro. Rosuvastatin accounts for greater than 87% of the pharmacologic action. Inhibitors of CYP2C9 increase the AUC by less than 2-fold. This interaction does not appear to be clinically significant. |
| Route of elimination: | Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. Following oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%). |
| Half Life: | 19 hours |
| Toxicity: | Generally well-tolerated. Side effects may include myalgia, constipation, asthenia, abdominal pain, and nausea. Other possible side effects include myotoxicity (myopathy, myositis, rhabdomyolysis) and hepatotoxicity. To avoid toxicity in Asian patients, lower doses should be considered. Pharmacokinetic studies show an approximately two-fold increase in peak plasma concentration and AUC in Asian patients (Philippino, Chinese, Japanese, Korean, Vietnamese, or Asian-Indian descent) compared to Caucasians patients. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
Enzymes
Transporters
